

U.S. Application No. 10/625,989
Reply to Final Office Action of November 18, 2008
Communication dated April 20, 2009

This Listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. (Previously presented) A pharmaceutical composition consisting essentially of the R enantiomer of equol (R-equol) and a pharmaceutically acceptable adjuvant, carrier or excipient.
2. (Previously presented) The pharmaceutical composition according to Claim 1 wherein the composition is made by isolating R-equol from a racemic mixture of S-equol and R-equol.
3. Canceled.
4. (Previously presented) The pharmaceutical composition according to Claim 1 wherein the R-equol has an enantiomeric purity of 90% minimum enantiomeric excess (EE).
5. (Previously presented) The pharmaceutical composition according to Claim 4 wherein the R-equol has an enantiomeric purity of 96% minimum EE.

U.S. Application No. 10/625,989
Reply to Final Office Action of November 18, 2008
Communication dated April 20, 2009

6. (Withdrawn) A food composition comprising an additive component comprising R-equol.
7. (Withdrawn) The food composition according to Claim 6, wherein the food comprises, per serving of food, at least about 1 mg, and up to about 300 mg R-equol.
8. (canceled)
9. (Withdrawn) A composition for topical application to skin, comprising R-equol and a vehicle.
10. (Withdrawn) The composition for topical application to skin according to Claim 9, comprising by weight at least 0.1% and up to 10%, of R-equol.
11. (Withdrawn) The composition according to Claim 9 where the R-equol is conjugated at the C-4' or C-7 position to form a conjugate selected from the group consisting of glucuronide, sulfate, acetate, propionate, glucoside, acetyl-glucoside, malonyl-glucoside, and mixtures thereof.

U.S. Application No. 10/625,989
Reply to Final Office Action of November 18, 2008
Communication dated April 20, 2009

12. (Withdrawn) A method of delivering R-equol to a mammal to prevent or treat a disease or associated condition, comprising administering to the mammal a composition comprising R-equol or a conjugated analog thereof.
13. (Withdrawn) The method according to Claim 12 wherein the composition is administered in an amount sufficient to produce a transient level of R-equol in the blood plasma of the mammal of at least 5 ng/mL.
14. (Withdrawn) The method according to Claim 12 where R-equol is conjugated at the C-4' or C-7 position to form a conjugate selected from the group consisting of glucuronide, sulfate, acetate, propionate, glucoside, acetyl-glucoside, malonyl-glucoside, and mixtures thereof.
15. (Withdrawn) The method according to Claim 12 where the composition is administered to the mammal orally in a dose amount of at least about 1 mg R-equol.
16. (Withdrawn) The method according to Claim 12 where disease comprises a hormone-dependent disease or condition selected from group consisting of cardiovascular disease, diminished blood vessel quality, lipid disorder, osteopenia, osteoporosis, liver disease, acute ovarian estrogen deficiency, benign breast cancer, breast cancer, benign prostate

U.S. Application No. 10/625,989
Reply to Final Office Action of November 18, 2008
Communication dated April 20, 2009

cancer, prostate cancer, skin cancer, colon cancer, vasomotor disturbances and night sweats associated with ovarian estrogen deficiency or antiestrogen therapy, impaired cognition, dementia, and brain disorders manifest as short or long-term memory loss.

17. (Withdrawn) The method according to Claim 16 wherein the hormone-dependent disease or condition is selected from group consisting of cardiovascular disease, diminished blood vessel quality, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency.
18. (Withdrawn) The method according to Claim 17 wherein the composition is administered in an amount sufficient to reduce the level of lipids in the blood or serum.
19. (Withdrawn) The method according to Claim 17 wherein the composition is administered in an amount sufficient to reduce the surrogate markers of bone turnover or prevent bone loss as measured by bone mineral density.
20. (Withdrawn) The method according to Claim 17 wherein the composition is administered in an amount sufficient to increase bone formation.
21. (Withdrawn) The method according to Claim 17 wherein the composition is

U.S. Application No. 10/625,989
Reply to Final Office Action of November 18, 2008
Communication dated April 20, 2009

administered in an amount sufficient to prevent osteoporosis and reduce bone fracture.

22-24. Canceled.

25. (Withdrawn) The method according to Claim 12 where disease comprises a non-hormone-dependent disease or condition selected from group consisting of inflammatory conditions of the gastrointestinal tract, the prostate, the breast, the skin and bone, and a condition associated with adenomatous polyps and familial polyposis.
26. Canceled.
27. (Withdrawn) The method according to Claim 25 wherein the non-hormone-dependent disease or condition is selected from group consisting of inflammatory conditions of the gastrointestinal tract, the prostate, the breast, the skin and bone.
28. (Withdrawn) The method according to Claim 12 wherein the composition is administered as a food or food additive.
29. (Previously presented) The composition according to Claim 1 where the R-equol is conjugated at the C-4' or C-7 position to form a conjugate selected from the group

U.S. Application No. 10/625,989
Reply to Final Office Action of November 18, 2008
Communication dated April 20, 2009

consisting of glucuronide, sulfate, acetate, propionate, glucoside, acetyl-glucoside, malonyl-glucoside, and mixtures thereof.

30. (Withdrawn) The composition according to Claim 9 wherein topical composition further comprises an agent selected from the group consisting of antifungals, vitamins, anti-inflammatory agents, antimicrobials, analgesics, nitric oxide synthase inhibitors, insect repellents, self-tanning agents, surfactants, moisturizers, stabilizers, preservatives, antiseptics, thickeners, lubricants, humectants, chelating agents, skin penetration enhancers, emollients, fragrances, and colorants and combinations thereof.
31. (Withdrawn) The composition according to Claim 30, wherein the commercial composition comprises by weight up to 10% of R-equol.
32. (Withdrawn) The composition according to Claim 31, wherein the commercial composition comprises by weight at least 0.1% of R-equol.
33. (Withdrawn) The composition according to Claim 30 where the R-equol is conjugated at the C-4' or C-7 position to form a conjugate selected from the group consisting of glucuronide, sulfate, acetate, propionate, glucoside, acetyl-glucoside, malonyl-glucoside, and mixtures thereof.

U.S. Application No. 10/625,989
Reply to Final Office Action of November 18, 2008
Communication dated April 20, 2009

34. (Previously presented) A pharmaceutical composition comprising enantiomerically pure R-equol as an active agent and a pharmaceutically acceptable adjuvant, carrier or excipient.
35. (Previously presented) A composition formulated for oral consumption or topical application, comprising R-equol, wherein the composition is substantially free of S-equol.
36. (Previously presented) The composition of claim 35, wherein the composition is a food product, a pharmaceutical, an over-the-counter (OTC) medicament, an ointment, a liquid, or a cream.